Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.

The oncologist - 1 Jan 2011

Baas Jara M, Krens Lisanne L, Guchelaar Henk-Jan, Morreau Hans, Gelderblom Hans

Abstract excerpt

BACKGROUND: Currently, only Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutational status is used as a decisional marker for epidermal growth factor receptor (EGFR) inhibitor therapy in colorectal cancer (CRC) patients. Concordance of KRAS status between primary tumors and metastases has always been considered to be close to perfect; however, cases of discordance have been reported. The actual rate of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21742964
DOI: 10.1634/theoncologist.2011-0024
PMCID: PMC3228174

Genes

KRAS
BRAF
EGFR
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.PMID 21742964Read ↗

Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.Semantic proximity Read ↗

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.Semantic proximity Read ↗

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.Semantic proximity Read ↗

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.Semantic proximity Read ↗

KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.Semantic proximity Read ↗

Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.Semantic proximity Read ↗

High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.Semantic proximity Read ↗

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.Semantic proximity Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.Semantic proximity Read ↗

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.